View Financial HealthEisai 配当と自社株買い配当金 基準チェック /46Eisai配当を支払う会社であり、現在の利回りは3.41%です。主要情報3.4%配当利回り0.0007%バイバック利回り総株主利回り3.4%将来の配当利回り3.6%配当成長1.0%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向106%最近の配当と自社株買いの更新Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more updateすべての更新を表示Recent updatesEisai Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Apr 21Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in JapanMar 28Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyMar 27Eisai Present New Data on Long-Term Real-World Treatment with LecanemabMar 23Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for NarcolepsyFeb 18Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDAJan 28Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)Jan 27Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's DiseaseJan 06Eisai Presents the Latest Findings on Time Savings with Continued Treatment with LeqembiDec 04+ 1 more updateEisai Co., Ltd. Presents New Data on Anti-Tau Antibody Etalanetug (E2814) At CTAD 2025Dec 02Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting DoseNov 28+ 1 more updateEisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusNov 25BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceNov 19Eisai Announces Leqembi Approval for IV Maintenance Treatment in the United KingdomNov 14Eisai Co., Ltd. Enters into Settlement Agreement with Torrent Pharmaceuticals LtdNov 09Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular CancerOct 29+ 1 more updateMerck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMAOct 28Health Canada Grants Authorization for Leqembi (Lecanemab)Oct 27Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)Oct 19Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07+ 1 more updateEisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from StudyOct 03Eisai Announces Leqembi Approval for IV Maintenance Treatment in ChinaOct 01Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24+ 1 more updateEisai Co., Ltd. Announces Etalanetug Granted FDA Fast Track DesignationSep 17Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025Sep 08Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025Sep 04Eisai Co., Ltd. Initiates Rolling Submission of Supplemental Biologics License Application to U.S. Food and Drug Administration for lecanemab-irmb Subcutaneous Autoinjector (SC-AI), LEQEMBI IQLIKSep 03Eisai Announces US FDA Approval of Leqembi IQKLIK®? (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseAug 30Eisai Co., Ltd. and Biogen Inc. Announce That the Anti-Amyloid Beta (Ab) Monoclonal Antibody "LEQEMBI" Has Been Launched in Austria on August 25, 2025 and Will Be Launched in Germany on September 1, 2025Aug 25+ 1 more updateEisai Presents Latest Findings on Lecanemab (Leqembi) At the Alzheimer's Association International ConferenceJul 31Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib MesylateMay 23Eisai Co., Ltd., Annual General Meeting, Jun 18, 2025May 15Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.May 09MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UKMay 02Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025Mar 06Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025Mar 04+ 2 more updatesEisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28Eisai Announces FDA Approval for Leqembi in USJan 27Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal AdenocarcinomaJan 24Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05Eisai Launches Leqembi in South KoreaNov 28+ 1 more updateEisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15+ 1 more updateEisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the USNov 02Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease ConferenceOct 31Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)Sep 16Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024Sep 04BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great BritainAug 22Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International ConferenceJul 31Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27+ 1 more updateEisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and ResearchJul 23Eisai Announces Approval for the Treatment of Alzheimer's Disease in IsraelJul 12Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in ChinaJun 28Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDAApr 02BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMar 14Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025Mar 02+ 3 more updatesEisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®Feb 23Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in ChinaJan 09Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20Dec 13Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial CarcinomaDec 08Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more updateEisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27Eisai Co., Ltd., Annual General Meeting, May 22, 2024Oct 20NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.Oct 18Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease ConferenceOct 16Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung CancerSep 23NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.Sep 08Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell CarcinomaAug 26Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad StudyJul 22+ 1 more updateEisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South KoreaJun 08New minor risk - Dividend sustainability Jun 08Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril AntibodyMay 22Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for LecanemabMay 19決済の安定と成長配当データの取得安定した配当: ESAI.Yの1株当たり配当金は過去10年間安定しています。増加する配当: ESAI.Yの配当金は過去10年間にわたって増加しています。配当利回り対市場Eisai 配当利回り対市場ESAI.Y 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (ESAI.Y)3.4%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (ESAI.Y) (最長3年)3.6%注目すべき配当: ESAI.Yの配当金 ( 3.41% ) はUS市場の配当金支払者の下位 25% ( 1.4% ) よりも高くなっています。高配当: ESAI.Yの配当金 ( 3.41% ) はUS市場の配当金支払者の上位 25% ( 4.23% ) と比較すると低いです。株主への利益配当収益カバレッジ: ESAI.Yは高い 配当性向 ( 105.5% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: ESAI.Yは合理的な 現金配当性向 ( 74.3% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 22:59終値2026/05/01 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eisai Co., Ltd. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research18 その他のアナリストを表示
Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17
Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more update
Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in JapanMar 28
Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines AgencyMar 27
Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21
Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for NarcolepsyFeb 18
Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDAJan 28
Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)Jan 27
Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26
Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's DiseaseJan 06
Eisai Presents the Latest Findings on Time Savings with Continued Treatment with LeqembiDec 04+ 1 more update
Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting DoseNov 28+ 1 more update
Eisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track StatusNov 25
BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease ConferenceNov 19
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular CancerOct 29+ 1 more update
Merck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMAOct 28
Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)Oct 19
Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07+ 1 more update
Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from StudyOct 03
Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24+ 1 more update
Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025Sep 08
Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025Sep 04
Eisai Co., Ltd. Initiates Rolling Submission of Supplemental Biologics License Application to U.S. Food and Drug Administration for lecanemab-irmb Subcutaneous Autoinjector (SC-AI), LEQEMBI IQLIKSep 03
Eisai Announces US FDA Approval of Leqembi IQKLIK®? (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseAug 30
Eisai Co., Ltd. and Biogen Inc. Announce That the Anti-Amyloid Beta (Ab) Monoclonal Antibody "LEQEMBI" Has Been Launched in Austria on August 25, 2025 and Will Be Launched in Germany on September 1, 2025Aug 25+ 1 more update
Eisai Presents Latest Findings on Lecanemab (Leqembi) At the Alzheimer's Association International ConferenceJul 31
PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib MesylateMay 23
Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.May 09
MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UKMay 02
Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16
Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28
Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal AdenocarcinomaJan 24
Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05
Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15+ 1 more update
Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the USNov 02
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01
Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease ConferenceOct 31
Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)Sep 16
BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great BritainAug 22
Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International ConferenceJul 31
Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27+ 1 more update
Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and ResearchJul 23
Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.May 17
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDAApr 02
BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMar 14
Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial CarcinomaDec 08
Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Nov 09+ 1 more update
Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's DiseaseOct 27
NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.Oct 18
Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease ConferenceOct 16
Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in JapanSep 25
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung CancerSep 23
NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.Sep 08
Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell CarcinomaAug 26
Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad StudyJul 22+ 1 more update
Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s DiseaseJul 07
Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory CommitteeJun 12
Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South KoreaJun 08
Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril AntibodyMay 22
Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for LecanemabMay 19